vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Tecnoglass Inc. (TGLS). Click either name above to swap in a different company.
Tecnoglass Inc. is the larger business by last-quarter revenue ($245.3M vs $191.2M, roughly 1.3× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 2.4%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 12.8%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Tecnoglass Inc. is a leading manufacturer of high-performance architectural glass, aluminum windows, doors, and associated building components. It primarily caters to residential and commercial construction sectors across North America and Latin America, offering custom, energy-efficient solutions for new construction and renovation projects.
AXSM vs TGLS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $245.3M |
| Net Profit | — | $26.1M |
| Gross Margin | — | 40.0% |
| Operating Margin | -33.1% | 18.3% |
| Net Margin | — | 10.6% |
| Revenue YoY | 57.4% | 2.4% |
| Net Profit YoY | — | -44.5% |
| EPS (diluted) | — | $0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $245.3M | ||
| Q3 25 | $171.0M | $260.5M | ||
| Q2 25 | $150.0M | $255.5M | ||
| Q1 25 | $121.5M | $222.3M | ||
| Q4 24 | $118.8M | $239.6M | ||
| Q3 24 | $104.8M | $238.3M | ||
| Q2 24 | $87.2M | $219.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $26.1M | ||
| Q3 25 | $-47.2M | $47.2M | ||
| Q2 25 | $-48.0M | $44.1M | ||
| Q1 25 | $-59.4M | $42.2M | ||
| Q4 24 | $-74.9M | $47.0M | ||
| Q3 24 | $-64.6M | $49.5M | ||
| Q2 24 | $-79.3M | $35.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 40.0% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | — | 44.7% | ||
| Q1 25 | — | 43.9% | ||
| Q4 24 | — | 44.5% | ||
| Q3 24 | — | 45.8% | ||
| Q2 24 | — | 40.8% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 18.3% | ||
| Q3 25 | -27.0% | 25.1% | ||
| Q2 25 | -24.5% | 24.0% | ||
| Q1 25 | -46.9% | 26.7% | ||
| Q4 24 | -61.1% | 28.0% | ||
| Q3 24 | -59.8% | 28.4% | ||
| Q2 24 | -89.5% | 23.3% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 10.6% | ||
| Q3 25 | -27.6% | 18.1% | ||
| Q2 25 | -32.0% | 17.3% | ||
| Q1 25 | -48.9% | 19.0% | ||
| Q4 24 | -63.1% | 19.6% | ||
| Q3 24 | -61.7% | 20.8% | ||
| Q2 24 | -91.0% | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $0.57 | ||
| Q3 25 | $-0.94 | $1.01 | ||
| Q2 25 | $-0.97 | $0.94 | ||
| Q1 25 | $-1.22 | $0.90 | ||
| Q4 24 | $-1.54 | $1.00 | ||
| Q3 24 | $-1.34 | $1.05 | ||
| Q2 24 | $-1.67 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $104.1M |
| Total DebtLower is stronger | $70.0M | $174.4M |
| Stockholders' EquityBook value | — | $713.1M |
| Total Assets | $713.6M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $104.1M | ||
| Q3 25 | $325.3M | $127.1M | ||
| Q2 25 | $303.0M | $140.9M | ||
| Q1 25 | $300.9M | $160.2M | ||
| Q4 24 | $315.4M | $137.5M | ||
| Q3 24 | $327.3M | $124.8M | ||
| Q2 24 | $315.7M | $129.5M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $174.4M | ||
| Q3 25 | — | $114.7M | ||
| Q2 25 | — | $110.6M | ||
| Q1 25 | — | $110.6M | ||
| Q4 24 | — | $111.1M | ||
| Q3 24 | — | $126.8M | ||
| Q2 24 | — | $144.7M |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $713.1M | ||
| Q3 25 | $73.7M | $764.0M | ||
| Q2 25 | $73.1M | $736.0M | ||
| Q1 25 | $53.2M | $685.1M | ||
| Q4 24 | $57.0M | $631.2M | ||
| Q3 24 | $92.9M | $613.3M | ||
| Q2 24 | $102.9M | $574.8M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $1.3B | ||
| Q3 25 | $669.3M | $1.2B | ||
| Q2 25 | $639.8M | $1.2B | ||
| Q1 25 | $596.7M | $1.1B | ||
| Q4 24 | $568.5M | $1.0B | ||
| Q3 24 | $561.5M | $996.3M | ||
| Q2 24 | $548.2M | $942.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.24× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $31.0M |
| Free Cash FlowOCF − Capex | — | $11.4M |
| FCF MarginFCF / Revenue | — | 4.7% |
| Capex IntensityCapex / Revenue | — | 8.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $31.0M | ||
| Q3 25 | $1.0M | $40.0M | ||
| Q2 25 | $-32.4M | $17.9M | ||
| Q1 25 | $-43.4M | $46.9M | ||
| Q4 24 | $-26.2M | $61.1M | ||
| Q3 24 | $-18.6M | $41.5M | ||
| Q2 24 | $-30.1M | $34.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $11.4M | ||
| Q3 25 | $988.0K | $21.2M | ||
| Q2 25 | $-32.4M | $-14.7M | ||
| Q1 25 | $-43.7M | $16.5M | ||
| Q4 24 | $-26.2M | $35.4M | ||
| Q3 24 | $-18.7M | $17.8M | ||
| Q2 24 | $-30.2M | $14.2M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 4.7% | ||
| Q3 25 | 0.6% | 8.2% | ||
| Q2 25 | -21.6% | -5.7% | ||
| Q1 25 | -36.0% | 7.4% | ||
| Q4 24 | -22.1% | 14.8% | ||
| Q3 24 | -17.9% | 7.5% | ||
| Q2 24 | -34.6% | 6.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 8.0% | ||
| Q3 25 | 0.0% | 7.2% | ||
| Q2 25 | 0.0% | 12.7% | ||
| Q1 25 | 0.3% | 13.7% | ||
| Q4 24 | 0.0% | 10.7% | ||
| Q3 24 | 0.1% | 9.9% | ||
| Q2 24 | 0.1% | 9.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 1.11× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.98× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
